Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial

Diabetes Care

Volumn 36, Issue 2, 2013, Pages 422-428

  Reyes Soffer, Gissette ^a   Ngai, Colleen I ^a   Lovato, Laura ^b   Karmally, Wahida ^a   Ramakrishnan, Rajasekhar ^a   Holleran, Stephen ^a   Ginsberg, Henry N ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN B48; APOLIPOPROTEIN C3; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEGRO; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; FEMALE; FENOFIBRATE; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; SIMVASTATIN;

EID: 84873823647     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2556     Document Type: Article

References (37)

1. Chahil TJ, Ginsberg HN. Diabetic dys-lipidemia. Endocrinol Metab Clin North Am 2006;35:491-510, vii-viii
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444
3. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipo-protein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219
4. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 2007;115: 450-458
5. Di Angelantonio E, Sarwar N, Perry P, et al.; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302: 1993-2000
6. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-316
7. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308
8. Enkhmaa B, Ozturk Z, Anuurad E, Berglund L. Postprandial lipoproteins and cardiovascular disease risk in diabetes mellitus. Curr Diab Rep 2010;10: 61-69
9. Carstensen M, Thomsen C, Gotzsche O, Holst JJ, Schrezenmeir J, Hermansen K. Differential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarction. Rev Diabet Stud 2004;1:175-184
10. Reyes-Soffer G, Holleran S, Karmally W, et al. Measures of postprandial lip-oproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus. J Lipid Res 2009;50: 1901-1909
11. Goldfine AB, Kaul S, Hiatt WR. Fibrates in the treatment of dyslipidemiasdtime for a reassessment. N Engl J Med 2011; 365:481-484
12. Jun M, Foote C, Lv J, et al. Effects of fi-brates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-1884
13. Roth EM, McKenney JM, Kelly MT, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hyper-triglyceridemia: a randomized, doubleblind study. Am J Cardiovasc Drugs2010; 10:175-186
14. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-1202
15. Derosa G, Maffioli P, Salvadeo SA, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin 2009;25:1973-1983
16. Goldberg AC, Bittner V, Pepine CJ, et al. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. Am J Cardiol 2011;107:898-905
17. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95: 462-468
18. Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
19. Ginsberg HN, Bonds DE, Lovato LC, et al.; ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99 (12A):56i-67i
20. Ginsberg HN, Jones J, Blaner WS, et al. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myo-cardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol 1995;15:1829-1838
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-502
22. Kinoshita M, Kojima M, Matsushima T, Teramoto T. Determination of apolipo-protein B-48 in serum by a sandwich ELISA. Clin Chim Acta 2005;351:115-120
23. Sumner AE. Ethnic differences in triglyceride levels and high-density lipo-protein lead to underdiagnosis of the metabolic syndrome in black children and adults. J Pediatr 2009;155:e7-e11
24. Syvänne M, Talmud PJ, Humphries SE, et al. Determinants of postprandial lipemia in men with coronary artery disease and low levels of HDL cholesterol. J Lipid Res 1997;38:1463-1472
25. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apoli-poprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res 1988;29: 925-936
26. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozilinmiddle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317: 1237-1245
27. Elam M, Lovato LC, Ginsberg H. Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Curr Opin Lipidol 2011;22:55-61
28. Reyes-Soffer G, Rondon-Clavo C, Ginsberg HN. Combination therapy with statin and fibrate in patients with dys-lipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opin Pharmac-other 2011;12:1429-1438
29. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007;30:1945-1951
30. Lai CQ, Arnett DK, Corella D, et al. Fe-nofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol 2007;27:1417-1425
31. Skoczynska A, Kreczynska B, Poreba R. Postprandial lipemia in diabetic men during hypolipemic therapy. Pol Arch Med Wewn 2009;119:461-468
32. McLauglin T, Abbasi F, Lamendola C, Leary E, Reaven GM. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a redutase inhibitor treatment of combined dyslipidemia. Metabolism 2002;51:1355-1359
33. Rivellese AA, De Natale C, Di Marino L, et al. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J Clin Endocrinol Metab 2004;89: 2153-2159
34. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996;15:5336-5348
35. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-2093
36. Malmendier CL, Lontie JF, Delcroix C, Dubois DY, Magot T, De Roy L. Apolipo-proteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 1989;77: 139-149
37. Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipo-protein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipo-protein lipase in vivo. J Clin Invest 1986; 78:1287-1295